Timing of Surgery in Patients with Triple Vessel Disease and Severe Aortic Stenosis After Ticagrelor Loading Dose
For patients with triple vessel disease and severe aortic stenosis who have received a ticagrelor loading dose, delay surgery for 2-3 days after ticagrelor discontinuation rather than the traditional 5-7 days, as this shorter interval has been shown to be non-inferior for bleeding risk while minimizing the thrombotic risk from prolonged antiplatelet interruption. 1
Recommended Surgical Timing Algorithm
Primary Recommendation: 2-3 Day Waiting Period
- Stop ticagrelor immediately and wait 2-3 days before proceeding with CABG surgery 1
- This shortened interval is supported by the most recent 2024 Canadian Cardiovascular Society guidelines, which represent a paradigm shift from older recommendations 1
- A randomized trial of 143 patients demonstrated that early CABG (2-3 days after ticagrelor cessation) had comparable severe/massive perioperative bleeding rates to delayed surgery (5-7 days): 4.6% vs 5.2% respectively (P = 0.03 for non-inferiority) 1
Supporting Evidence for Shortened Interval
- Large cohort data confirms safety: In a Swedish cohort of 1,266 ticagrelor-treated ACS patients, CABG-related bleeding was similar between 3-5 days versus >5 days of discontinuation (OR 0.93; 95% CI 0.53-1.64) 1
- Critical threshold identified: European registry data (2,482 patients) showed that discontinuation within 2 days was associated with increased bleeding, but 2-3 days was safe 1
Alternative Timing Considerations Based on Bleeding Risk
Standard Approach (Most Patients)
- 2-3 days after ticagrelor discontinuation for most CABG procedures 1
High Bleeding Risk Scenarios
- If the patient has additional high bleeding risk factors, consider extending to 3-5 days as suggested by the 2022 CHEST guidelines for non-cardiac surgery 2
- The FDA label recommends interrupting ticagrelor for 5 days prior to surgery with major bleeding risk, though this represents older, more conservative guidance 3
Emergency/Urgent Situations
- Do not delay if the clinical situation is unstable (e.g., ongoing ischemia, hemodynamic instability, mechanical complications)
- Accept increased bleeding risk as the thrombotic risk outweighs bleeding concerns 3
- Consider platelet transfusion intraoperatively if surgery cannot be delayed 4, 5
Critical Management Points
Aspirin Management
- Continue aspirin perioperatively through the surgery whenever possible 2, 1
- Evidence from the ATACAS trial (>8,000 patients) showed aspirin use within 5 days of CABG reduced mortality without increasing re-operation for bleeding 2
- This is particularly important given the high thrombotic risk in triple vessel disease with severe aortic stenosis
Post-Operative Antiplatelet Strategy
- Resume ticagrelor as soon as hemostasis is achieved post-operatively 3
- Restart within 24 hours if bleeding is controlled 2
- Plan for dual antiplatelet therapy (DAPT) with aspirin + ticagrelor post-CABG, as this reduces saphenous vein graft failure (OR 0.50; 95% CI 0.31-0.79) 1
Important Caveats and Pitfalls
Individual Variability in Platelet Recovery
- There is substantial interindividual variability in platelet function recovery after ticagrelor discontinuation 5
- At 72 hours, 25% of patients still had inadequate platelet recovery in one study 5
- If available, consider platelet function testing to guide timing in borderline cases, though this is not routinely necessary 4, 5
Avoid These Common Errors
- Do not routinely wait 5-7 days based on outdated recommendations—this unnecessarily increases thrombotic risk 1
- Do not stop aspirin unless absolutely necessary for bleeding control 2, 1
- Do not delay resumption of antiplatelet therapy post-operatively beyond what is needed for hemostasis 3
Thrombotic Risk Considerations
- Discontinuing ticagrelor increases risk of MI, stroke, and death in coronary artery disease patients 3
- The combination of triple vessel disease and severe aortic stenosis represents very high thrombotic risk
- Minimizing the antiplatelet-free interval is critical 1, 3